OBJECTIVE: The aim was to study a possible relationship between CD69 expression on lymphocytes and interleukin-15 (IL-15) levels in synovial fluid (SF) from patients with different inflammatory arthropathies. METHODS: CD69 expression was assessed by two-color flow cytometry on different subsets of synovial fluid lymphocytes (SFL) obtained from patients with diagnoses of rheumatoid arthritis (RA), seronegative spondyloarthropathy (SSd), and crystal-associated arthritis (CAA). The IL-15 levels in synovial fluid supernatants were measured by enzyme-linked immunoassay (ELISA). RESULTS: No significant differences between the three groups of arthropathies were observed in the distribution of synovial fluid lymphocyte subsets. CD69-positive SFL were mainly CD3-, CD45RO-, and CCR5-positive cells. Although no significant differences in the percentage of CD69-positive lymphocytes were observed between the three groups of patients, the highest level of CD69 expression on lymphocytes was observed in RA patients (mean fluorescence intensity 37.9 +/- 5.2 compared to 17.5 +/- 3.3 in SSd and 12.4 +/- 2.6 in CAA, P = 0.007 and P < 0.001, respectively). In addition, the expression of CD69 on SFL from RA correlated with their respective IL-15 levels measured in SF supernatants. CONCLUSION: Our data provide in vivo evidence of the putative role that IL-15 can play in the high expression of CD69 on SFL from RA patients.
OBJECTIVE: The aim was to study a possible relationship between CD69 expression on lymphocytes and interleukin-15 (IL-15) levels in synovial fluid (SF) from patients with different inflammatory arthropathies. METHODS:CD69 expression was assessed by two-color flow cytometry on different subsets of synovial fluid lymphocytes (SFL) obtained from patients with diagnoses of rheumatoid arthritis (RA), seronegative spondyloarthropathy (SSd), and crystal-associated arthritis (CAA). The IL-15 levels in synovial fluid supernatants were measured by enzyme-linked immunoassay (ELISA). RESULTS: No significant differences between the three groups of arthropathies were observed in the distribution of synovial fluid lymphocyte subsets. CD69-positive SFL were mainly CD3-, CD45RO-, and CCR5-positive cells. Although no significant differences in the percentage of CD69-positive lymphocytes were observed between the three groups of patients, the highest level of CD69 expression on lymphocytes was observed in RApatients (mean fluorescence intensity 37.9 +/- 5.2 compared to 17.5 +/- 3.3 in SSd and 12.4 +/- 2.6 in CAA, P = 0.007 and P < 0.001, respectively). In addition, the expression of CD69 on SFL from RA correlated with their respective IL-15 levels measured in SF supernatants. CONCLUSION: Our data provide in vivo evidence of the putative role that IL-15 can play in the high expression of CD69 on SFL from RApatients.
Authors: A Julià; A Fernandez-Nebro; F Blanco; A Ortiz; J D Cañete; J Maymó; M Alperi-López; B Fernández-Gutierrez; A Olivè; H Corominas; A Erra; I Acosta-Colman; A Alonso; M López-Lasanta; R Tortosa; J Tornero; S Marsal Journal: Pharmacogenomics J Date: 2015-04-21 Impact factor: 3.550
Authors: Girak Kim; Mi Seon Jang; Young Min Son; Min Ji Seo; Sang Yun Ji; Seung Hyun Han; In Duk Jung; Yeong-Min Park; Hyun Jung Jung; Cheol-Heui Yun Journal: PLoS One Date: 2013-04-26 Impact factor: 3.240
Authors: Raquel Celis; Núria Planell; José L Fernández-Sueiro; Raimon Sanmartí; Julio Ramírez; Isidoro González-Álvaro; José L Pablos; Juan D Cañete Journal: Arthritis Res Ther Date: 2012-04-27 Impact factor: 5.156
Authors: Isidoro González-Álvaro; Ana M Ortiz; José María Alvaro-Gracia; Santos Castañeda; Belen Díaz-Sánchez; Inmaculada Carvajal; J Alberto García-Vadillo; Alicia Humbría; J Pedro López-Bote; Esther Patiño; Eva G Tomero; Esther F Vicente; Pedro Sabando; Rosario García-Vicuña Journal: PLoS One Date: 2011-12-29 Impact factor: 3.240
Authors: Isidoro González-Alvaro; Carmen Domínguez-Jiménez; Ana M Ortiz; Vanessa Núñez-González; Pedro Roda-Navarro; Elena Fernández-Ruiz; David Sancho; Francisco Sánchez-Madrid Journal: Arthritis Res Ther Date: 2006 Impact factor: 5.156
Authors: I González-Alvaro; A M Ortiz; C Domínguez-Jiménez; A Aragón-Bodi; B Díaz Sánchez; F Sánchez-Madrid Journal: Ann Rheum Dis Date: 2008-10-28 Impact factor: 19.103
Authors: Elisenda Alari-Pahissa; Laura Notario; Elena Lorente; Javier Vega-Ramos; Ana Justel; Daniel López; José A Villadangos; Pilar Lauzurica Journal: PLoS One Date: 2012-10-30 Impact factor: 3.240